Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II clinical pharmacology, safety, and tolerability of ziprasidone in schizophrenia
jRCT2080221713Phase 2
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ziprasidone in schizophrenia, sponsored by Meiji Seika Pharma Co., Ltd.
02
Drugs
ziprasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221713.